Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 4
2005 4
2006 2
2007 5
2008 1
2009 1
2010 2
2011 1
2012 2
2013 8
2014 2
2015 7
2016 10
2017 12
2018 4
2019 9
2020 9
2021 19
2022 15
2023 12
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma.
Rade M, Grieb N, Weiss R, Sia J, Fischer L, Born P, Boldt A, Fricke S, Franz P, Scolnick J, Venkatraman L, Xu S, Kloetzer C, Heyn S, Kubasch AS, Baber R, Wang SY, Bach E, Hoffmann S, Ussmann J, Schetschorke B, Hell S, Schwind S, Metzeler KH, Herling M, Jentzsch M, Franke GN, Sack U, Köhl U, Platzbecker U, Reiche K, Vucinic V, Merz M. Rade M, et al. Among authors: herling m. Nat Cancer. 2024 Apr 19. doi: 10.1038/s43018-024-00763-8. Online ahead of print. Nat Cancer. 2024. PMID: 38641734
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.
Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmerman MW, Eder T, Abdallah DI, Maurer B, Wagner C, Schönefeldt S, Spirk K, Pichler A, Pemovska T, Schweicker C, Pölöske D, Hubanic E, Jungherz D, Müller TA, Aung MMK, Orlova A, Pham HTT, Zimmel K, Krausgruber T, Bock C, Müller M, Dahlhoff M, Boersma A, Rülicke T, Fleck R, de Araujo ED, Gunning PT, Aittokallio T, Mustjoki S, Sanda T, Hartmann S, Grebien F, Hoermann G, Haferlach T, Staber PB, Neubauer HA, Look AT, Herling M, Moriggl R. Suske T, et al. Among authors: herling m. J Clin Invest. 2024 Apr 15;134(8):e168536. doi: 10.1172/JCI168536. J Clin Invest. 2024. PMID: 38618957 Free PMC article.
Post-transplant-cyclophosphamide and short-term Everolimus as graft-versus-host-prophylaxis in patients with relapsed/refractory lymphoma and myeloma-Final results of the phase II OCTET-EVER trial.
Richardson T, Scheid C, Herling M, Frenzel LP, Herling C, Aguilar MRC, Theurich S, Hallek M, Holtick U. Richardson T, et al. Among authors: herling m. Eur J Haematol. 2024 Apr 14. doi: 10.1111/ejh.14210. Online ahead of print. Eur J Haematol. 2024. PMID: 38616351
Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?
Schwind S, Bischof L, Bill M, Grimm J, Ussmann J, Backhaus D, Brauer D, Thanh TP, Merz M, Franke GN, Metzeler KH, Vucinic V, Herling M, Platzbecker U, Jentzsch M. Schwind S, et al. Among authors: herling m. Hemasphere. 2024 Mar 18;8(3):e55. doi: 10.1002/hem3.55. eCollection 2024 Mar. Hemasphere. 2024. PMID: 38501048 Free PMC article. No abstract available.
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.
Ferrari M, Righi M, Baldan V, Wawrzyniecka P, Bulek A, Kinna A, Ma B, Bughda R, Akbar Z, Srivastava S, Gannon I, Robson M, Sillibourne J, Jha R, El-Kholy M, Amin OM, Kokalaki E, Banani MA, Hussain R, Day W, Lim WC, Ghongane P, Hopkins JR, Jungherz D, Herling M, Welin M, Surade S, Dyson M, McCafferty J, Logan D, Cordoba S, Thomas S, Sewell A, Maciocia P, Onuoha S, Pule M. Ferrari M, et al. Among authors: herling m. Nat Commun. 2024 Feb 21;15(1):1583. doi: 10.1038/s41467-024-45854-3. Nat Commun. 2024. PMID: 38383515 Free PMC article.
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N, Deconinck E, Mehta P, Walker I, Herling M, Garnache-Ottou F, Gabarin N, Campbell CJV, Duell J, Moshe Y, Mughal T, Mohty M, Angelucci E. Pemmaraju N, et al. Among authors: herling m. Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):e130-e137. doi: 10.1016/j.clml.2023.12.010. Epub 2023 Dec 20. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38267355 Free article. Review.
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
Herling M, Dearden C, Zaja F, El-Sharkawi D, Ding W, Bellido M, Khot A, Tick L, Jacobsen E, Eyre TA, Roos-Weil D, Kadia T, Lucchini E, Pflug N, Davids MS, Pena G, Mukherjee N, Badawi M, Vizkelety T, Staber PB. Herling M, et al. Blood Adv. 2024 Feb 27;8(4):842-845. doi: 10.1182/bloodadvances.2023012248. Blood Adv. 2024. PMID: 38190628 Free PMC article. Clinical Trial. No abstract available.
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.
Fischer L, Grieb N, Born P, Weiss R, Seiffert S, Boldt A, Fricke S, Franz P, Heyn S, Kubasch AS, Baber R, Weidner H, Wang SY, Bach E, Hoffmann S, Ussmann J, Kirchberg J, Hell S, Schwind S, Metzeler KH, Herling M, Jentzsch M, Franke GN, Sack U, Reiche K, Köhl U, Platzbecker U, Vucinic V, Merz M. Fischer L, et al. Among authors: herling m. Leukemia. 2024 Feb;38(2):372-382. doi: 10.1038/s41375-023-02129-y. Epub 2024 Jan 6. Leukemia. 2024. PMID: 38184754 Free PMC article.
Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.
Bischof L, Ussmann J, Grimm J, Bill M, Brauer D, Backhaus D, Herrmann L, Merz M, Herling M, Metzeler KH, Franke GN, Vucinic V, Platzbecker U, Schwind S, Jentzsch M. Bischof L, et al. Among authors: herling m. Leukemia. 2024 Jan;38(1):198-201. doi: 10.1038/s41375-023-02072-y. Epub 2023 Oct 25. Leukemia. 2024. PMID: 37880479 Free PMC article.
129 results